Cargando…

Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis

BACKGROUND: Although chemotherapeutic regimens containing a taxane or platinum agent have been widely recommended for unfavourable carcinoma of unknown primary (CUP), no evidence exists for the superiority of any administered regimens. To date, the efficacy has been mostly assessed in the limited se...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, J, Hahn, S, Kim, D-W, Kim, J, Kang, S N, Rha, S Y, Lee, K B, Kang, J-H, Park, B-J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3553519/ https://www.ncbi.nlm.nih.gov/pubmed/23175147 http://dx.doi.org/10.1038/bjc.2012.516

Ejemplares similares

Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI
por: Lankester, K J, et al.
Publicado: (2005)

Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer
por: Kim, S T, et al.
Publicado: (2005)

Gemcitabine-oxaliplatin combination for ovarian cancer resistant to taxane-platinum treatment: a phase II study from the GINECO group
por: Ray-Coquard, I, et al.
Publicado: (2009)

Unfavourable expression of pharmacologic markers in mucinous colorectal cancer
por: Glasgow, S C, et al.
Publicado: (2005)

Cerebellar location may predict an unfavourable prognosis in paediatric high-grade glioma
por: Karremann, M, et al.
Publicado: (2013)

Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum
por: Yoon, D H, et al.
Publicado: (2012)

Survival benefit of taxane plus platinum in recurrent ovarian cancer with non-clear cell, non-mucinous histology
por: Kajiyama, Hiroaki, et al.
Publicado: (2014)

A systematic review of taxane-containing regimens for metastatic breast cancer
por: Ghersi, D, et al.
Publicado: (2005)

Hypersensitivity Reactions to Platinum Agents and Taxanes
por: Tsao, Lulu R., et al.
Publicado: (2021)

Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer
por: Lee, C K, et al.
Publicado: (2011)

The impact of prior platinum therapy on survival in patients with metastatic urothelial cancer receiving vinflunine
por: Harshman, L C, et al.
Publicado: (2013)

Randomised phase II trial of docetaxel and sunitinib in patients with metastatic gastric cancer who were previously treated with fluoropyrimidine and platinum
por: Yi, J H, et al.
Publicado: (2012)

Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer
por: Xenidis, N, et al.
Publicado: (2013)

Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study
por: Pittman, K B, et al.
Publicado: (2006)

Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer
por: Liu, Ying, et al.
Publicado: (2015)

Platinum drugs and taxanes: can we overcome resistance?
por: Sazonova, Elena V., et al.
Publicado: (2021)

Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival
por: Jernigan, Amelia M., et al.
Publicado: (2013)

Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
por: Massard, C, et al.
Publicado: (2007)

Prognostic Value of Glioma Cancer Stem Cell Isolation in Survival of Primary Glioblastoma Patients
por: Kong, Byung Ho, et al.
Publicado: (2014)

A phase I and pharmacokinetic study of novel taxane BMS-188797 and cisplatin in patients with advanced solid tumours
por: du Bois, A, et al.
Publicado: (2006)

Irinotecan plus carboplatin for patients with carcinoma of unknown primary site
por: Yonemori, K, et al.
Publicado: (2009)

Expression of Endothelin-A-Receptor predicts unfavourable response to neoadjuvant chemotherapy in locally advanced breast cancer
por: Wülfing, P, et al.
Publicado: (2004)

Acute-Onset Vitreous Hemorrhage of Unknown Origin before Vitrectomy: Causes and Prognosis
por: Kim, Dong Yoon, et al.
Publicado: (2015)

Treatable Subsets in Cancer of Unknown Primary Origin
por: Sumi, Hajime, et al.
Publicado: (2001)

Cancer patients' awareness of clinical trials, perceptions on the benefit and willingness to participate: Korean perspectives
por: Kim, J W, et al.
Publicado: (2008)

Biological Markers and Response to Neoadjuvant Taxane-Based Chemotherapy in Patients with Locally Advanced Breast Cancer
por: El-sayed, Mohamed I., et al.
Publicado: (2012)

Phase I trial of axitinib combined with platinum doublets in patients with advanced non-small cell lung cancer and other solid tumours
por: Kozloff, M F, et al.
Publicado: (2012)

Early Primary Biliary Cirrhosis: A New Association with Erythema Nodosum of Unknown Origin
por: Gatselis, Nikolaos K., et al.
Publicado: (2010)

Taxanes and platinum derivatives impair Schwann cells via distinct mechanisms
por: Imai, Satoshi, et al.
Publicado: (2017)

Adaptive dosing and platinum–DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours
por: Veal, G J, et al.
Publicado: (2007)

Phase I trial of the novel taxane BMS-184476 administered in combination with carboplatin every 21 days
por: Bilenker, J H, et al.
Publicado: (2004)

On the Unfavourable Influence of Sudden Change of Climate
por: Bennet, J. Henry
Publicado: (1863)

Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer
por: Kümmel, S, et al.
Publicado: (2006)

Unfavourable results in pollicisation
por: Thatte, Mukund R., et al.
Publicado: (2013)

Unfavourable results in hypospadias
por: Agrawal, Karoon, et al.
Publicado: (2013)

Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy
por: Kang, H J, et al.
Publicado: (2005)

A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer
por: Kang, H J, et al.
Publicado: (2008)

A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen
por: Culine, S, et al.
Publicado: (2006)

Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer
por: von Plessen, C, et al.
Publicado: (2006)

The benefit of taxane-based therapies over fluoropyrimidine plus platinum (FP) in the treatment of esophageal cancer: a meta-analysis of clinical studies
por: Wang, Tao, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pi2pud0r7k8bk2vtaa5sa7ktm8